Hodgkin Lymphoma, Adult Clinical Trial
Official title:
A Phase 2 Multi-Center Study Evaluating the Safety and Efficacy of CD30-Directed Genetically Modified Autologous T Cells (CD30.CAR-T) in Adult and Pediatric Patients With Relapsed or Refractory Classical Hodgkin Lymphoma
This is a two-part, Phase 2, multicenter, open-label, single arm study to evaluate the safety and efficacy of autologous CD30.CAR-T in adult and pediatric subjects with relapsed or refractory CD30+ classical Hodgkin Lymphoma.
The Pilot part of the study will evaluate the safety, tolerability, and preliminary antitumor efficacy of CD30.CAR-T. The Pivotal part of the study will evaluate antitumor efficacy and further evaluate safety and tolerability. All study eligibility requirements, assessments, procedures, and follow-up are the same for patients in both Pilot and Pivotal parts of the study. Subjects who meet eligibility criteria will have their blood drawn by leukapheresis for manufacture the CD30.CAR-T cells. Subjects are allowed bridging chemotherapy, as per Investigator choice, while waiting for production of CD30.CAR-T. Lymphodepletion (LD) with fludarabine and bendamustine will be administered for 3 consecutive days starting on Day -5 to Day -3, prior to CD30.CAR-T infusion, which will be administered on Day 0 as a single IV infusion. Depending on disease status, eligible subjects may receive up to a total of two CD30.CAR-T infusions at the same dose, each with preceding LD chemotherapy. Subjects will be closely monitored for safety and efficacy throughout the Treatment Period until the end of study (EOS) visit at Month 24. Subjects will be followed for survival, withdrawal of consent or study closure, whichever occurs first. Health Related Quality of Life assessments will also be collected throughout the study. After the EOS visit, subjects will enter the long-term follow-up phase (LTFU) which will include survival follow-up, additional safety, efficacy and biomarker assessments, as clinically indicated. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04653649 -
CAR T-cells Against CD30 (HSP-CAR30) for Relapsed/ Refractory Hodgkin and T-cell Lymphoma.
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04636255 -
Physical Capacity in Hodgkin Lymphoma Survivors
|
N/A | |
| Recruiting |
NCT05597761 -
Immunogenicity of COVID-19 Vaccination in Autologous HSCT or CAR-T Cells Recipients
|
||
| Active, not recruiting |
NCT03535948 -
Elderly Hodgkin Lymphoma Patients Treated With Chemoradiotherapy
|
||
| Completed |
NCT03155425 -
PD-1 Antibody SHR-1210 in Patients With Relapsed or Refractory Classic Hodgkin's Lymphoma
|
Phase 2 | |
| Recruiting |
NCT03260101 -
Non-interventional, Long-term Follow-up of Subjects Who Completed ApoGraft-01 Study
|
||
| Recruiting |
NCT04776265 -
RWE of Brentuximab Vedotin Consolidation in Patients With RR HL Who Receive Salvage Chemotherapy and ASCT
|
||
| Recruiting |
NCT04378647 -
BREntuximab Vedotin in SEcond LIne Therapy BEfore Transplant
|
Phase 2 | |
| Recruiting |
NCT04758650 -
Study of 68GaNOTA-Anti-MMR-VHH2 in Oncological Lesions, Cardiovascular Atherosclerosis, Syndrome With Abnormal Immune Activation and sarcoïdosis
|
Phase 2 | |
| Recruiting |
NCT05137886 -
PD-1 Inhibitor Combined With Decitabine Followed by ASCT as Second-line Therapy for Relapsed or Refractory Classic Hodgkin's Lymphoma
|
Phase 2 | |
| Completed |
NCT04292626 -
Molecular Imaging of Lymphoma Using Labeled Technetium-99m 1-Thio-D-Glucose
|
Phase 1 | |
| Recruiting |
NCT04638790 -
First Line Chemotherapy for Classical Hodgkin Lymphoma in Russia (HL-Russia-1)
|
Phase 3 | |
| Completed |
NCT01578967 -
Induction Chemo w/ABVD Followed by Brentuximab Vedotin Consolidation in Newly Diagnosed, Non-Bulky Stage I/II Hodgkin Lymphoma
|
N/A | |
| No longer available |
NCT03914885 -
Compassionate Use Re-Infusion of ATLCAR.CD30
|